125 related articles for article (PubMed ID: 16336973)
1. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
Chromik J; Schnürer E; Georg Meyer R; Wehler T; Tüting T; Wölfel T; Huber C; Herr W
J Immunol Methods; 2006 Jan; 308(1-2):77-89. PubMed ID: 16336973
[TBL] [Abstract][Full Text] [Related]
2. MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide.
Prato S; Maxwell T; Pinzón-Charry A; Schmidt CW; Corradin G; López JA
Eur J Immunol; 2005 Mar; 35(3):681-9. PubMed ID: 15688345
[TBL] [Abstract][Full Text] [Related]
3. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies.
Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR
J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775
[TBL] [Abstract][Full Text] [Related]
4. IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity.
Lattanzi L; Rozera C; Marescotti D; D'Agostino G; Santodonato L; Cellini S; Belardelli F; Gavioli R; Ferrantini M
Immunobiology; 2011 May; 216(5):537-47. PubMed ID: 21093097
[TBL] [Abstract][Full Text] [Related]
5. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells.
Hatakeyama N; Tamura Y; Sahara H; Suzuki N; Suzuki K; Hori T; Mizue N; Torigoe T; Tsutsumi H; Sato N
Exp Hematol; 2006 Feb; 34(2):197-207. PubMed ID: 16459188
[TBL] [Abstract][Full Text] [Related]
6. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.
Sugano M; Conway TF; Kelleher RJ; Sugiyama Y; Chen FA; Bankert RB; Bernstein SH
J Exp Clin Cancer Res; 2001 Jun; 20(2):175-82. PubMed ID: 11484971
[TBL] [Abstract][Full Text] [Related]
7. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells.
Dieckmann D; Schultz ES; Ring B; Chames P; Held G; Hoogenboom HR; Schuler G
Int Immunol; 2005 May; 17(5):621-35. PubMed ID: 15824067
[TBL] [Abstract][Full Text] [Related]
8. HLA class I epitope discovery in type 1 diabetes.
van Endert P; Hassainya Y; Lindo V; Bach JM; Blancou P; Lemonnier F; Mallone R
Ann N Y Acad Sci; 2006 Oct; 1079():190-7. PubMed ID: 17130554
[TBL] [Abstract][Full Text] [Related]
9. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals.
Reijonen H; Elliott JF; van Endert P; Nepom G
J Immunol; 1999 Aug; 163(3):1674-81. PubMed ID: 10415074
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
11. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
12. Efficiency and mechanism of antigen-specific CD8+ T-cell activation using synthetic long peptides.
Zandvliet ML; Kester MG; van Liempt E; de Ru AH; van Veelen PA; Griffioen M; Guchelaar HJ; Falkenburg JH; Meij P
J Immunother; 2012; 35(2):142-53. PubMed ID: 22306902
[TBL] [Abstract][Full Text] [Related]
13. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
14. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells.
Zehn D; Cohen CJ; Reiter Y; Walden P
Eur J Immunol; 2004 Jun; 34(6):1551-60. PubMed ID: 15162424
[TBL] [Abstract][Full Text] [Related]
15. IRAP identifies an endosomal compartment required for MHC class I cross-presentation.
Saveanu L; Carroll O; Weimershaus M; Guermonprez P; Firat E; Lindo V; Greer F; Davoust J; Kratzer R; Keller SR; Niedermann G; van Endert P
Science; 2009 Jul; 325(5937):213-7. PubMed ID: 19498108
[TBL] [Abstract][Full Text] [Related]
16. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
17. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Cancer Sci; 2008 Aug; 99(8):1633-42. PubMed ID: 18754877
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
20. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]